May 19th 2025
The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
AAPS PharmSci 360: LBFs and Tackling Oral Biologic Formulations
October 22nd 2024At AAPS PharmSci 360, Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer Health, at Catalent Pharma Solutions, discussed lipid-based formulations and tackling bioavailability challenges for oral biologics.
CPHI Milan 2024: Heparin and Heparinoids in Pharmaceuticals
October 10th 2024Pharmaceutical Technology Europe sat down with Joan Bassa, Human Health Business Unit Director at Bioiberica, to talk about the history of heparin, its uses in pharmaceuticals, and what heparinoids have to offer the industry.
AAPS PharmSci 360 2024: Predictive Models for Poorly Soluble Drugs
October 10th 2024Pharmaceutical Technology sat down with Niloufar Salehi, advisor at Eli Lilly & Company, to talk about the session she is moderating at AAPS PharmSci 360 2024, Symposium: An Accelerated Development of Poorly Soluble Drugs Using Predictive Tool.